Solomon et al. [33] reported the prevalence of ANA to be 31%, extractable nuclear antigen or SSA antibodies to be 4%, rheumatoid factor to be 1.1%, anti-cardiolipin antibodies (IgG, IgM or IgA) to be 16%, and lupus anticoagulant (LA) to be 2.2% in a group of 91 female MS patients. This evidence concerns the gene RO60 and myeloid sarcoma.